产品和服务 / 产品类型 / 重组蛋白 / 细胞因子 & 细胞因子受体

活性验证

Recombinant Human CCL2/MCP-1 Protein (RP01657)

Recombinant Human CCL2/MCP-1 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 10-15 kDa.

Recombinant Human CCL2/MCP-1 chemoattract THP-1 cells. The ED50 for this effect is typically 13.56-54.24 ng/mL.

All(2)|
货号: RP01657

促销价:   ¥780
货    期:现货产品
抗体定制
服务咨询
|
扫码下单
享受积分

详细信息

种属
Human
表达宿主
Pichia
Calculated MW
8.69 kDa
Observed MW
15-20 kDa
标签
NO-tag
纯度
> 95% by SDS-PAGE.
内毒素
<0.1EU/μg
制剂
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
描述
Recombinant Human CCL2/MCP-1 Protein is produced by Pichia expression system. The target protein is expressed with sequence (Gln24-Thr99) of human CCL2/MCP-1 (Accession #NP_002973.1) fused with no additional amino acid.
储存
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月;
复溶之后,蛋白溶液在-20°C及以下可保存3个月,在2-8℃可保存1周。
生物活性
Measured by its ability to chemoattract THP-1 cells. The ED50 for this effect is typically 13.56-54.24 ng/mL.
复溶
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底,如果粉末浮起,开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL(请注意蛋白复溶浓度不能低于0.1 mg/mL),室温平衡5-10 min保证充分溶解,复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存,建议复溶时添加载体蛋白或者稳定剂(如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖),同时将复溶后的蛋白溶液按照需求进行分装,储存于-20°C至-80°C,随取随用,避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度,快速计算您需要添加溶液的体积吧!
=
÷

客户数据及评论 (0)

折叠内容

背景信息

Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B.